Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC TrialEva Versteijne, Mustafa Suker, Karin Groothuis et al.|Journal of Clinical Oncology|2020Cited by 1.1k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trialReinhard Dummer, Keith T. Flaherty, Paolo A. Ascierto et al.|The Lancet Oncology|2018Cited by 1k
Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trialReinhard Dummer, Keith T. Flaherty, Paolo A. Ascierto et al.|The Lancet Oncology|2018Cited by 586
RET as a Diagnostic and Therapeutic Target in Sporadic and Hereditary Endocrine TumorsJan Willem B. de Groot, Robert M.W. Hofstra|Endocrine Reviews|2006Cited by 357
First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer GroupMarinde J. G. Bond, Johanneke H.M.J.V. Vestjens, Robbert J. van Alphen et al.|The Lancet Oncology|2023Cited by 168